WHO Pharmaceuticals Newsletter 1998, No. 09&10
(1998; 23 pages)
Table des matières
Ouvrir ce répertoire et afficher son contenuRegulatory decisions
Ouvrir ce répertoire et afficher son contenuDrug surveillance
Fermer ce répertoireNew developments
Afficher le documentFomepizole - approved as an antidote in ethylene glycol poisoning: USA
Afficher le documentInfliximab - approved for Crohn’s disease: USA
Afficher le documentLeflunomide - oral treatment approved for active rheumatoid arthritis: USA
Afficher le documentLepirudin - approved for heparin-associated thrombocytopenia: UK
Afficher le documentOral contraceptives - approved for emergency use: USA
Afficher le documentRotavirus vaccine - approved to help prevent rotaviral disease: USA
Afficher le documentThalidomide - approved for use in leprosy: USA
Afficher le documentNew indications
Afficher le documentNew formulations
Afficher le documentNewly approved products
Ouvrir ce répertoire et afficher son contenuMedical devices
Ouvrir ce répertoire et afficher son contenuGeneral information
Ouvrir ce répertoire et afficher son contenuMedication errors
Ouvrir ce répertoire et afficher son contenuVeterinary medicine
 

Oral contraceptives - approved for emergency use: USA

United States of America. The Food and Drug Administration has approved a marketing application for the Preven Emergency Contraceptive Kit (Gynetics) containing the oral contraceptive pills for postcoital emergency contraception, packaged with a urinary pregnancy test.

The application is based on a regimen - also known as the Yuzpe regimen - that consists of two oral contraceptive pills containing ethinyl estradiol and levonorgestrel taken within 72 hours of unprotected intercourse and two pills taken 12 hours later. When used in this manner, the treatment is about 75% effective in preventing pregnancy.

The most common adverse effects are nausea, vomiting, menstrual irregularities, breast tenderness, headache, abdominal pain and cramps, and dizziness.

Although emergency contraception is not as effective as proper use of a regular contraceptive method, it substantially reduces the chances of becoming pregnant when used within 72 hours after unprotected sexual intercourse.

[See also p.9 above - levonorgestrel]

References: FDA Talk Paper T98-49 dated 2 September 1998.

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013